New Potential Monotherapeutic Candidates for Helicobacter pylori: Some Pyridinazo Compounds Having Both Urease Enzyme Inhibition and Anti-Helicobacter pylori Effectiveness

Creative Commons License

Kantar C., Baltaş N., Alpay Karaoğlu Ş., Şaşmaz S.

PHARMACEUTICAL CHEMISTRY JOURNAL, vol.55, no.3, pp.246-252, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1007/s11094-021-02406-z
  • Journal Name: PHARMACEUTICAL CHEMISTRY JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE
  • Page Numbers: pp.246-252
  • Keywords: azo dyes, anti-Helicobacter pylori, urease enzyme inhibition, ANTIOXIDANT CAPACITY, BENZIMIDAZOLE, GROWTH
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

To contribute to the monotherapeutic approach to Helicobacter pylori, some new pyridinazo compounds containing natural phenols such as eugenol and guaiacol were synthesized and their antioxidant capacities, urease enzyme inhibition and anti-Helicobacter pylori effect were investigated. This monotherapeutic approach suggests that a single synthetic drug with both a strong urease enzyme inhibitor and effective antibiotic properties can be used to treat Helicobacter pylori infection As expected, all newly obtained pyridinazo compounds have been found to have both urease enzyme inhibitor properties and anti-Helicobacter pylori activity.